4D Molecular Therapeutics (FDMT) Assets Average: 2021-2025
Historic Assets Average for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $448.8 million.
- 4D Molecular Therapeutics' Assets Average fell 26.67% to $448.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.8 million, marking a year-over-year decrease of 26.67%. This contributed to the annual value of $450.1 million for FY2024, which is 49.61% up from last year.
- 4D Molecular Therapeutics' Assets Average amounted to $448.8 million in Q3 2025, which was down 9.27% from $494.7 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Assets Average's 5-year high stood at $625.0 million during Q2 2024, with a 5-year trough of $247.8 million in Q3 2021.
- Its 3-year average for Assets Average is $458.6 million, with a median of $484.9 million in 2024.
- Its Assets Average has fluctuated over the past 5 years, first soared by 109.55% in 2024, then decreased by 26.67% in 2025.
- Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Assets Average stood at $297.1 million in 2021, then decreased by 8.77% to $271.0 million in 2022, then rose by 29.43% to $350.8 million in 2023, then soared by 65.99% to $582.2 million in 2024, then dropped by 26.67% to $448.8 million in 2025.
- Its Assets Average stands at $448.8 million for Q3 2025, versus $494.7 million for Q2 2025 and $538.1 million for Q1 2025.